Table: Daito -2017/18 parent results
Jul 13 (Reuters)-
Daito Pharamaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
May 31, 2018 May 31, 2017 May 31, 2019 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 39.65 37.79
(+4.9 pct) (+4.3 pct)
Operating 3.77 3.12
(+20.7 pct) (-3.9 pct)
Recurring 3.95 3.17
(+24.5 pct) (-7.4 pct)
Net 2.89 2.16
(+33.8 pct) (-9.3 pct)
EPS 230.55 yen 172.32 yen
Ann Div 33.00 yen 33.00 yen 36.00 yen
-Q2 Div 15.00 yen 15.00 yen 18.00 yen
-Q4 Div 18.00 yen 18.00 yen 18.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results